MedinCell’s polymers protect small molecule, peptide, and protein APIs during release (days, weeks, months—even up to a year); this proprietary technology also guards against competitors.
MedinCell has developed an extremely rapid formulation development process, and a technology that is compatible with a broad range of APIs. This means rapid validation of the extended release capacity for key drug compounds in development.
By tailoring formulations to minimize high Cmax (initial burst), MedinGel can help reduce off-target effects for improved patient compliance and safety.
MedinCell tunes each formulation through a number of control axes; shifting the PEG, PLA and other components to optimize the target PK profile.
Multiple Administration Routes
In addition to Subcutaneous, additional routes of administration are being tested (Intra-articular and Ocular) with MedinGel.
MedinCell has the technology and experience to offer a complete solution for your APIs.
We Design Best-in-Class Formulations
MedinCell has been engaged by multiple pharmaceutical partners to design formulations for molecules that require intraarticular administration. Contact our business development team to explore exciting new options for multi-month local delivery.